{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Anaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Disseminated intravascular coagulation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Febrile neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Iron deficiency anaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Leukopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Lymphopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Activated partial thromboplastin time prolonged"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Lymphocyte count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Lymphocyte count increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Neutrophil count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Platelet count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"White blood cell count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"Aspartate aminotransferase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Blood albumin decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Blood alkaline phosphatase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Blood bicarbonate decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Blood bilirubin increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Blood creatinine increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Blood triglycerides increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Gamma-glutamyltransferase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Lipase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Hyperglycaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Hyperkalaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Hypermagnesaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Hypernatraemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hypertriglyceridaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Hypoalbuminaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Hypocalcaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hypoglycaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Hypokalaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Hypomagnesaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Hyponatraemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Haematuria"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Haemoglobinuria"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Proteinuria"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as AEs. The TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug, up to 30 days after the last dose of study drug (approximately 7 months).","groups":[{"description":"Participants received intravenous infusion of moxetumomab pasudotox 40 µg/kg on Days 1, 3, and 5 of each 28-day cycle for up to 6 cycles, until documentation of complete response, progressive disease, initiation of alternate therapy, or unacceptable toxicity.","id":"OG000","title":"Moxetumomab Pasudotox 40 µg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population included participants who received at least 1 dose of moxetumomab pasudotox.","reportingStatus":"POSTED","timeFrame":"From the start of study treatment (Day 1) through 4-6 weeks after last dose of Cycle 6 (28-day cycle) (approximately 7 months)","title":"Number of Participants With Abnormal Clinical Laboratory Results Reported as TEAEs","type":"SECONDARY","unitOfMeasure":"Participants"}